Isoindolones derivatives as MEK kinase inhibitors and methods of use
US8492427B2 · kind B2 · utility
34Cited by
3References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2009 |
| Grant date | Jul 23, 2013 |
| Priority date | — |
| Expiry date | Jul 1, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.